Human cytomegalovirus-encoded pUL7 is a novel CEACAM1-like molecule responsible for promotion of angiogenesis

mBio

Volumn 5, Issue 6, 2014, Pages

  Macmaniman, Jason D ^a   Meuser, Andrew ^a   Botto, Sara ^a   Smith, Patricia P ^a   Liu, Fenyong ^b   Jarvis, Michael A ^a,c   Nelson, Jay A ^a   Caposio, Patrizia ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; INTERLEUKIN 6; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN UL10; PROTEIN UL7; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN UL7; STAT3 PROTEIN; UNCLASSIFIED DRUG; CD66 ANTIGENS; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; MATRIX PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; GENE DELETION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MUTATIONAL ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STRUCTURE; TRANSIENT EXPRESSION; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; AMINO ACID SEQUENCE; CYTOMEGALOVIRUS; GENETIC RECOMBINATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; SEQUENCE ALIGNMENT;

HUMAN HERPESVIRUS 5;

AMINO ACID SEQUENCE; ANTIGENS, CD; CELL ADHESION MOLECULES; CYTOMEGALOVIRUS; HUMANS; INTERLEUKIN-6; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINATION, GENETIC; SEQUENCE ALIGNMENT; VIRAL MATRIX PROTEINS; VIRUS REPLICATION;

EID: 84920911056     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mbio.02035-14     Document Type: Article

References (47)

1. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS. 1993. Risk factors for chronic rejection in renal allograft recipients. Transplantation 55:752-756. http://dx.doi.org/10.1097/00007890-199304000-00013.
2. Melnick JL, Adam E, DeBakey ME. 1998. The link between CMV and atherosclerosis. Infect. Med. 15:479-486.
3. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394. http://dx.doi.org/10.1126/science.8023160.
4. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62: 3347-3350.
5. Orloff SL, Yin Q, Corless CL, Orloff MS, Rabkin JM, Wagner CR. 2000. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation 69:1295-1303. http://dx.doi.org/10.1097/00007890-200004150-00015.
6. Orloff SL, Streblow DN, Soderberg-Naucler C, Yin Q, Kreklywich C, Corless CL, Smith PA, Loomis CB, Mills LK, Cook JW, Bruggeman CA, Nelson JA, Wagner CR. 2002. Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants. Transplantation 73:679-688. http://dx.doi.org/10.1097/00007890-200203150-00005.
7. Streblow DN, Kreklywich C, Yin Q, De La Melena VT, Corless CL, Smith PA, Brakebill C, Cook JW, Vink C, Bruggeman CA, Nelson JA, Orloff SL. 2003. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J. Virol. 77:2182-2194. http://dx.doi.org/10.1128/JVI.77.3.2182-2194.2003.
8. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O’Connell JB, Resta S, Dunn D, Gamberg P, Ratkovec RM, Richenbacher WE, Millar RC, DuMond C, DeAmond B, Sullivan V, Cheney T, Buhles W, Stinson EB. 1992. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N. Engl. J. Med. 326: 1182-1186. http://dx.doi.org/10.1056/NEJM199204303261803.
9. Valantine HA, Gao SZ, Menon SG, Renlund DG, Hunt SA, Oyer P, Stinson EB, Brown BW, Jr, Merigan TC, Schroeder JS. 1999. Impact of prophylactic immediate post-transplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebocontrolled study. Circulation 100:61-66. http://dx.doi.org/10.1161/01.CIR.100.1.61.
10. Streblow DN, Kreklywich CN, Andoh T, Moses AV, Dumortier J, Smith PP, DeFilippis V, Fruh K, Nelson JA, Orloff SL. 2008. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am. J. Transplant. 8:277-287. http://dx.doi.org/10.1111/j.1600-6143.2007.02062.x.
11. Dumortier J, Streblow DN, Moses AV, Jacobs JM, Kreklywich CN, Camp D, Smith RD, Orloff SL, Nelson JA. 2008. Human cytomegalovirus secretomes contains factors that induce angiogenesis and wound healing. J. Virol. 82:6524-6535. http://dx.doi.org/10.1128/JVI.00502-08.
12. Botto S, Streblow DN, DeFilippis V, White L, Kreklywich CN, Smith PP, Caposio P. 2011. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood 117:352-361. http://dx.doi.org/10.1182/blood-2010-06-291245.
13. Engel P, Pérez-Carmona N, Albà MM, Robertson K, Ghazal P, Angulo A. 2011. Human cytomegalovirus UL7, a homologue of the SLAM-family receptor CD229, impairs cytokine production. Immunol. Cell Biol. 89: 753-766. http://dx.doi.org/10.1038/icb.2011.55.
14. Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, Zhu H, Liu F. 2003. Functional profiling of a human cytomegalovirus genome. Proc. Natl. Acad. Sci. U. S. A. 100:14223-14228. http://dx.doi.org/10.1073/pnas.2334032100.
15. Sekulin K, Görzer I, Heiss-Czedik D, Puchhammer-Stöckl E. 2007. Analysis of the variability of CMV strains in the RL11D domain of the RL11 multigene family. Virus Genes 35:577-583. http://dx.doi.org/10.1007/s11262-007-0158-0.
16. Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ, McGeoch DJ, Hayward GS. 2003. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J. Gen. Virol. 84(Pt 1):7-28. http://dx.doi.org/10.1099/vir.0.18606-0.
17. Gu A, Tsark W, Holmes KV, Shively JE. 2009. Role of Ceacam1 in VEGF induced vasculogenesis of murine embryonic stem cell-derived embryoid bodies in 3D culture. Exp. Cell Res. 315:1668-1682. http://dx.doi.org/10.1016/j.yexcr.2009.02.026.
18. Ergün S, Kilik N, Ziegeler G, Hansen A, Nollau P, Götze J, Wurmbach JH, Horst A, Weil J, Fernando M, Wagener C. 2000. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector ofvascular endothelial growth factor. Mol. Cell 5:311-320. http://dx.doi.org/10.1016/S1097-2765(00)80426-8.
19. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA, III, Kouzarides T, Martignetti JA, et al. 1990. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol. 154:125-169.
20. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85: 1301-1312. http://dx.doi.org/10.1099/vir.0.79888-0.
21. Shikhagaie M, Mercé-Maldonado E, Isern E, Muntasell A, Albà MM, López-Botet M, Hengel H, Angulo A. 2012. The HCMV-specific UL1 gene encodes a late phase glycoprotein incorporated in the virion envelope. J. Virol. 86:4091-4101. http://dx.doi.org/10.1128/JVI.06291-11.
22. Gray-Owen SD, Blumberg RS. 2006. CEACAM1: contact-dependent control of immunity. Nat. Rev. Immunol. 6:433-446. http://dx.doi.org/10.1038/nri1864.
23. Horst AK, Ito WD, Dabelstein J, Schumacher U, Sander H, Turbide C, Brümmer J, Meinertz T, Beauchemin N, Wagener C. 2006. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. J. Clin. Invest. 116:1596-1605. http://dx.doi.org/10.1172/JCI24340.
24. Kuespert K, Pils S, Hauck CR. 2006. CEACAMs: their role in physiology and pathophysiology. Curr. Opin. Cell Biol. 18:565-571. http://dx.doi.org/10.1016/j.ceb.2006.08.008.
25. Turbide C, Kunath T, Daniels E, Beauchemin N. 1997. Optimal ratios of biliary glycoprotein isoforms required for inhibition of colonic tumor cell growth. Cancer Res. 57:2781-2788.
26. Singer BB, Scheffrahn I, Obrink B. 2000. The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res. 60:1236-1244.
27. Duncan SR, Paradis IL, Yousem SA, Similo SL, Grgurich WF, Williams PA, Dauber JH, Griffith BP. 1992. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am. Rev. Respir. Dis. 146: 1419-1425. http://dx.doi.org/10.1164/ajrccm/146.6.1419.
28. Humbert M, Delattre RM, Fattal S, Rain B, Cerrina J, Dartevelle P, Simonneau G, Duroux P, Galanaud P, Emilie D. 1993. In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation 56:623-627. http://dx.doi.org/10.1097/00007890-199309000-00024.
29. Simmons P, Kaushansky K, Torok-Storb B. 1990. Mechanisms of cytomegalovirus mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 87:1386-1390. http://dx.doi.org/10.1073/pnas.87.4.1386.
30. Müller MM, Klaile E, Vorontsova O, Singer BB, Obrink B. 2009. Homophilic adhesion and CEACAME1-S regulate dimerization of CEACAME1-L and recruitment of SHP-2 and c-Src. J. Cell Biol. 187: 569-581. http://dx.doi.org/10.1083/jcb.200904150.
31. Kamimura D, Ishihara K, Hirano T. 2003. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149:1-38. http://dx.doi.org/10.1007/s10254-003-0012-2.
32. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. 1998. Interleukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem. J. 334:297-314.
33. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. 2009. CCL2 and interleukin-6 promote survival of human CD11b_ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J. Biol. Chem. 284:34342-34354. http://dx.doi.org/10.1074/jbc.M109.042671.
34. Moreno A, Villar ML, Cámara C, Luque R, Cespón C, González-Porqué P, Roy G, López-Jiménez J, Bootello A, Santiago ER. 2001. Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells. Blood 97:242-249. http://dx.doi.org/10.1182/blood.V97.1.242.
35. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. 1994. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6:87-91. http://dx.doi.org/10.1016/1043-4666(94)90013-2.
36. Fischer P, Hilfiker-Kleiner D. 2007. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res. Cardiol. 102:393-411. http://dx.doi.org/10.1007/s00395-007-0674-z.
37. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. 2003. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem. J. 374:1-20. http://dx.doi.org/10.1042/BJ20030407.
38. Kurdi M, Booz GW. 2009. JAK redux: a second look at the regulation and role of JAKs in the heart. Am. J. Physiol. Heart Circ. Physiol. 297: H1545-H1556. http://dx.doi.org/10.1152/ajpheart.00032.2009.
39. Lorenz K, Schmitt JP, Vidal M, Lohse MJ. 2009. Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int. J. Biochem. Cell Biol. 41: 2351-2355. http://dx.doi.org/10.1016/j.biocel.2009.08.002.
40. Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile- Ramos A, Lira SA, Söderberg-Nauclér C, Smit MJ. 2010. HCMVencoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci. Signal. 3:ra58. http://dx.doi.org/10.1126/scisignal.2001180.
41. Smith IL, Taskintuna I, Rahhal FM, Powell HC, Ai E, Mueller AJ, Spector SA, Freeman WR. 1998. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. 116:178-185.
42. Murphy E, Yu D, Grimwood J, Schmutz J, Dickson M, Jarvis MA, Hahn G, Nelson JA, Myers RM, Shenk TE. 2003. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 100:14976-14981. http://dx.doi.org/10.1073/pnas.2136652100.
43. Britt WJ, Jarvis M, Seo JY, Drummond D, Nelson J. 2004. Rapid genetic engineering of human cytomegalovirus using a lambda phage linear recombination system: demonstration that pp28 (UL99) is essential for production of infectious virus. J. Virol. 78:539-543. http://dx.doi.org/10.1128/JVI.78.1.539-543.2004.
44. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. 2005. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33:e36. http://dx.doi.org/10.1093/nar/gni035.
45. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh DA, Schlaepfer DD. 2003. Differential regulation of cell motility and invasion by FAK. J. Cell Biol. 160:753-767. http://dx.doi.org/10.1083/jcb.200212114.
46. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F, Mattison K, Altschuler Y, Nelson JA. 1999. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99:511-520. http://dx.doi.org/10.1016/S0092-8674(00)81539-1.
47. Murphy EA, Streblow DN, Nelson JA, Stinski MF. 2000. The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J. Virol. 74:7108-7118. http://dx.doi.org/10.1128/JVI.74.15.7108-7118.2000.